Literature DB >> 24287796

Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms.

M Procopio1, M Barale, S Bertaina, S Sigrist, R Mazzetti, M Loiacono, G Mengozzi, E Ghigo, M Maccario.   

Abstract

Cardiometabolic disorders have been associated with primary hyperparathyroidism (PHPT), while the relationship of cardiovascular risk score (CRS) and metabolic syndrome (MS) with different clinical presentation of PHPT remains undefined. Our aim was to evaluate CRS, MS and its components in PHPT looking for their correlation to different clinical forms. In 68 consecutive PHPT patients and 68 matched controls, CRS, MS and its components were assessed to perform an observational case-control study at an ambulatory referral center for Bone Metabolism Diseases. Patients were stratified in symptomatic and asymptomatic PHPT; these latter were divided in high-risk and low-risk subgroups for end-organ damage. An increased proportion of PHPT patients had intermediate-high CRS and MS (mean, 95 % Confidence Interval (CI) 51.5 %, 39.6-63.3 and 20.6 %, 11.0-30.2, respectively, p < 0.02 vs. controls). Intermediate-high CRS was prevalent both in symptomatic and low-risk asymptomatic PHPT while MS resulted prevalent in low-risk asymptomatic but not in symptomatic PHPT. Type 2 DM, IFG, mixed dyslipidemia, hypertriglyceridemia, HDL-hypocholesterolemia, and LDL-hypercholesterolemia predominated in low-risk asymptomatic, while only LDL-hypercholesterolemia prevailed also in symptomatic PHPT. In patients and controls without cardiometabolic risk factors, HOMA-IR index was significantly increased in PHPT vs. controls (p < 0.03) and associated to total calcium (R = 0.73; p < 0.001). By multivariate analysis low-risk asymptomatic PHPT predicted MS after adjusting for age, sex, and BMI. Our data show an increased frequency of intermediate-high CRS both in symptomatic and low-risk asymptomatic PHPT while MS prevails in low-risk asymptomatic PHPT, supporting the potential for cardiovascular morbidity and mortality also in this form.

Entities:  

Mesh:

Year:  2013        PMID: 24287796     DOI: 10.1007/s12020-013-0091-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  37 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?

Authors:  Jeffrey L Anderson; Ryan C Vanwoerkom; Benjamin D Horne; Tami L Bair; Heidi T May; Donald L Lappé; Joseph B Muhlestein
Journal:  Am Heart J       Date:  2011-08       Impact factor: 4.749

3.  Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening.

Authors:  Emil Hagström; Ewa Lundgren; Jonas Rastad; Per Hellman
Journal:  Eur J Endocrinol       Date:  2006-07       Impact factor: 6.664

4.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

5.  Serum calcium is positively correlated with fasting plasma glucose and insulin resistance, independent of parathyroid hormone, in male patients with type 2 diabetes mellitus.

Authors:  Toru Yamaguchi; Ippei Kanazawa; Shin Takaoka; Toshitsugu Sugimoto
Journal:  Metabolism       Date:  2011-04-12       Impact factor: 8.694

6.  Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism.

Authors:  Karen M Tordjman; Marianna Yaron; Elena Izkhakov; Etty Osher; Galina Shenkerman; Yonit Marcus-Perlman; Naftali Stern
Journal:  Eur J Endocrinol       Date:  2010-05       Impact factor: 6.664

7.  Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism.

Authors:  Ilkay Cakir; Kursad Unluhizarci; Fatih Tanriverdi; Gulsah Elbuken; Zuleyha Karaca; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2012-02-12       Impact factor: 3.633

8.  Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism.

Authors:  S Kumar; A O Olukoga; C Gordon; E B Mawer; M France; J P Hosker; M Davies; A J Boulton
Journal:  Clin Endocrinol (Oxf)       Date:  1994-01       Impact factor: 3.478

9.  Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism.

Authors:  Jens Bollerslev; Thord Rosen; Charlotte L Mollerup; Jörgen Nordenström; Marek Baranowski; Celina Franco; Ylva Pernow; Gunhild A Isaksen; Kristin Godang; Thor Ueland; Svante Jansson
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

10.  Insulin secretion, insulin sensitivity and hepatic insulin extraction in primary hyperparathyroidism before and after surgery.

Authors:  A Kautzky-Willer; G Pacini; B Niederle; G Schernthaner; R Prager
Journal:  Clin Endocrinol (Oxf)       Date:  1992-08       Impact factor: 3.478

View more
  15 in total

1.  The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism.

Authors:  Kristin Godang; Karolina Lundstam; Charlotte Mollerup; Stine Lyngvi Fougner; Ylva Pernow; Jörgen Nordenström; Thord Rosen; Svante Jansson; Mikael Hellström; Jens Bollerslev; Ansgar Heck
Journal:  Endocr Connect       Date:  2018-07-16       Impact factor: 3.335

2.  Emerging data on cardiovascular risk in primary hyperparathyroidism.

Authors:  Jessica Pepe; Sara Piemonte; Cristiana Cipriani; Mirella Cilli; Salvatore Minisola
Journal:  Endocrine       Date:  2014-09-10       Impact factor: 3.633

3.  Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up.

Authors:  Halit Diri; Kursad Unluhizarci; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2014-04-11       Impact factor: 3.633

4.  Evaluation of left ventricle functions by tissue Doppler, strain, and strain rate echocardiography in patients with primary hyperparathyroidism.

Authors:  Didem Ozdemir; Gulhan Yuksel Kalkan; Nihal Akar Bayram; Eda Demir Onal; Reyhan Ersoy; Engin Bozkurt; Bekir Cakir
Journal:  Endocrine       Date:  2014-03-28       Impact factor: 3.633

5.  Carotid intima-media thickness is not associated with vitamin D and PTH levels in patients admitted to an Internal Medicine Department.

Authors:  Vincenzo Carnevale; Rita Minonne; Angela De Matthaeis; Maria Antonietta Annese; Patrizia Tabacco; Palmina D'Arcangelo; Graziella D'Amico; Alfredo Scillitani
Journal:  Endocrine       Date:  2014-02-13       Impact factor: 3.633

6.  Increased frequency of impaired fasting glucose and isolated systolic hypertension in Paget's disease of bone.

Authors:  Marco Barale; Vincenzo Cappiello; Ezio Ghigo; Massimo Procopio
Journal:  Endocrine       Date:  2018-10-03       Impact factor: 3.633

7.  Effect of 1-year oral cholecalciferol on a metabolic profile and blood pressure in poor-controlled type 2 diabetes mellitus: an open-label randomized controlled pilot study.

Authors:  M Barale; R Rossetto Giaccherino; E Ghigo; M Procopio
Journal:  J Endocrinol Invest       Date:  2020-08-17       Impact factor: 4.256

8.  High prevalence of metabolic syndrome in a mestizo group of adult patients with primary hyperparathyroidism (PHPT).

Authors:  Victoria Mendoza-Zubieta; Gloria A Gonzalez-Villaseñor; Guadalupe Vargas-Ortega; Baldomero Gonzalez; Claudia Ramirez-Renteria; Moises Mercado; Mario A Molina-Ayala; Aldo Ferreira-Hermosillo
Journal:  BMC Endocr Disord       Date:  2015-04-03       Impact factor: 2.763

Review 9.  Parathyroid hormone pulsatility: physiological and clinical aspects.

Authors:  Silvia Chiavistelli; Andrea Giustina; Gherardo Mazziotti
Journal:  Bone Res       Date:  2015-01-27       Impact factor: 13.567

10.  Primary Hyperparathyroidism: The Influence of Bone Marrow Adipose Tissue on Bone Loss and of Osteocalcin on Insulin Resistance.

Authors:  Maira L Mendonça; Sérgio L Batista; Marcello H Nogueira-Barbosa; Carlos E G Salmon; Francisco J A de Paula
Journal:  Clinics (Sao Paulo)       Date:  2016-08       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.